Direct targeting of αvβ3 integrin on tumor cells with a monoclonal antibody, Abegrin ™

Molecular Cancer Therapeutics

Volumn 5, Issue 12, 2006, Pages 3122-3129

  Mulgrew, Kathy ^a   Kinneer, Krista ^a   Yao, Xiao Tao ^a   Ward, Beth K ^a   Damschroder, Melissa M ^a   Walsh, Bill ^a   Mao, Su Yau ^a   Gao, Changshou ^a   Kiener, Peter A ^a   Coats, Steve ^a   Kinch, Michael S ^a   Tice, David A ^a  

^a MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABEGRIN; BEVACIZUMAB; MONOCLONAL ANTIBODY LM 609; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; DRUG TARGETING; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CANCER; LUNG CANCER; MELANOMA; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; SKIN CANCER; SOLID TUMOR; SPECIES DIFFERENCE; TUMOR VASCULARIZATION; ANIMAL; BIOSYNTHESIS; DRUG SCREENING; IMMUNOLOGY; MOUSE MUTANT; NEOPLASM; NUDE MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HUMANS; INTEGRIN ALPHAVBETA3; MICE; MICE, NUDE; MICE, SCID; NEOPLASMS; SPECIES SPECIFICITY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33846188062     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0356     Document Type: Article

References (29)

1. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005;23:1147-57.
2. 3 for angiogenesis. Science 1994; 264:569-71.
3. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994; 79:1157-64.
4. 3 blocks human breast cancer growth and angiogenesis in human skin [see comments]. J Clin Invest 1995;96:1815-22.
5. Kumar CC. Integrin UX3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr Drug Targets 2003;4:123-31.
6. 3 integrin in the development of osteolytic bone metastases: a pharmacological target for alternative therapy? Calcif Tissue Int 2002;71:293-9.
7. vβ3 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions. Cancer Res 1997;57:1554-60.
8. 3 integrin in melanomas and nevi. Hum Pathol 1999;30: 562-7.
9. Gingras MC, Roussel E, Bruner JM, Branch CD, Moser RP. Comparison of cell adhesion molecule expression between glioblastoma multiforme and autologous normal brain tissue. J Neuroimmunol 1995;57:143-53.
10. Ria R, Vacca A, Ribatti D, Di Raimondo F, Merchionne F, Dammacco F. α(v)β(3) integrin engagement enhances cell invasiveness in human multiple myeloma. Haematologica 2002;87:836-45.
11. v integrins and their ligand vitronectin in normal ovarian epithelium and in ovarian carcinoma. Gynecol Oncol 1996; 62:260-7.
12. 3. Anticancer Res 1999; 19:1529-32.
13. 3 expression by bone-residing breast cancer metastases. Diagn Mol Pathol 1996;5:127-35.
14. 3-Specific humanized mAb. Proc Natl Aced Sci U S A 1998;95:6037-42.
15. 3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. Clin Cancer Res 2005;11:7851-60.
16. 3 integrins by swapping a short diverse sequence of the β subunit. J Biol Chem 1997;272: 19794-800.
17. 3. Cancer Res 2006;66:9673-81.
18. Cheresh DA. Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor. Proc Natl Acad Sci U S A 1987;84:6471-5.
19. 3-mediated melanoma cell adhesion to fibrinogen and its plasmic fragments. J Biol Chem 1992;267: 5070-7.
20. Iannello A, Ahmad A. Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal anti-bodies. Cancer Metastasis Rev 2005;24:487-99.
21. Taborda CP, Rivera J, Zaragoza O, Casadevall A. More is not necessarily better: prozone-like effects in passive immunization with IgG. J Immunol 2003;170:3621-30.
22. Gomez-Roman VR, Patterson LJ, Venzon D, et al. Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J Immunol 2005;174:2185-9.
23. Parker SJ, Sadlon TA, Gordon DL. Enhancement of NK cell-mediated antibody-dependent lysis of recombinant gp120-coated CD4 cells by complement. J Infect Dis 1995;171:186-9.
24. Sinclair AL, Habeshaw JA, Muir L, et al. Antibody-dependent cell-mediated cytotoxicity: comparison between HTLV-I and HIV-1 assays. AIDS 1988;2:465-72.
25. Holmes MJ, Callow KA, Childs RA, Tyrrell DA. Antibody dependent cellular cytotoxicity against coronavirus 229E-infected cells. Br J Exp Pathol 1986;67:581-6.
26. Ball ED, Kadushin JM, Schacter B, Fanger MW. Studies on the ability of monoclonal antibodies to selectively mediate complement-dependent cytotoxicity of human myelogenous leukemia blast cells. J Immunol 1982; 128:1476-81.
27. Asano Y, Albrecht P, Stagno S, Takahashi M. Potentiation of neutralization of Varicella-Zoster virus to antibody to immunoglobulin. J Infect Dis 1982;146:524-9.
28. 2 fragments administered intranasally. J Infect Dis 1996;173:1123-8.
29. Taborda CP, Casadevall A. Immunoglobulin M efficacy against Cryptococcus neoformans: mechanism, dose dependence, and prozone-like effects in passive protection experiments. J Immunol 2001;166: 2100-7.